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Summary. Insulin Degrading Enzyme (IDE) is an
endopeptidase that degrades insulin and glucagon. Ide
gene has been associated with type-2 diabetes mellitus
(DM2). However, the physiological role(s) of IDE in
glucose homeostasis and its potential therapeutic benefit
remain not completely known. 
To contribute in the understanding of IDE's role in
glucose metabolism, we analyzed IDE protein level in
pancreatic islets from two hyperinsulinemic mouse
models, db/db and high-fat diet (HFD) mice, as well as
in human islets from DM2 patients treated with oral
hypoglycemic agents (OHAs) or insulin. IDE protein
level was detected by staining and by western-blot.
INS1E cells, rat and human islets were treated with
insulin and IDE protein level was studied.
We have shown for the first time IDE staining in
rodent and human tissue, using the proper negative
control, IDE null mouse tissue. Our staining indicates
that IDE is expressed in both beta- and alpha-cells, with
higher expression in alpha-cells. Db/db and HFD mice
islets showed increased IDE protein level. Interestingly,
human islets from DM2 patients treated with OHAs
showed decreased IDE protein level in beta-cells.
Meanwhile, islets from insulin-treated DM2 patients
showed augmented IDE protein level compared to
OHAs patients, pointing to an upregulation of IDE
protein level stimulated by insulin. These data correlate
nicely with insulin-stimulated upregulation of IDE in
cultured INS1E cells, as well as in rat and human islets.
In conclusion, our study shows that IDE is expressed
in pancreatic beta- and alpha-cells of both rodents and
humans, having higher expression in alpha-cells.
Furthermore, insulin stimulates IDE protein level in
pancreatic beta-cells. These results may have
implications in how DM2 patient’s treatment affects
their beta-cell function.
Key words: Insulin-degrading enzyme, Type 2 diabetes,
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Introduction
Insulin-degrading enzyme (IDE) is a metalloprotease
that degrades several peptides including insulin and
glucagon. It is localized in cytoplasm, cell membranes,
some organelles and it is also secreted into the
extracellular space. IDE is ubiquitously expressed,
supporting a multifunctional role. Although its most
known function is to degrade circulating insulin in liver
and kidneys (Duckworth et al., 1998; Pivovarova et al.,
2016). The Ide gene is localized in one of the
susceptibility loci linked to type-2 diabetes mellitus
(DM2) (Gu et al., 2004; Schulze et al., 2007; Sladek et
al., 2007), and some Ide polymorphisms have been
associated with the DM2 population (Karamohamed et
al., 2003; Kwak et al., 2008).
It has been proposed that IDE inhibition could be
used therapeutically for DM2 treatment (Pivovarova et
al., 2016; Tang, 2016). This line of reasoning is based on
the assumption that in vivo inhibition of IDE could be
used to reduce insulin clearance and thereby augment
insulin levels in patients with DM2. Ideally, these
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inhibitors should preferentially modulate IDE activity on
insulin, without affecting degradation of other IDE
substrates. Of note, IDE inhibitors that bind away from
the catalytic cleft improve glucose tolerance in mice,
suggesting that IDE might be a promising therapeutic
target for the treatment of DM2 (Maianti et al., 2014).
However, other IDE inhibitors have not exhibited similar
results (Durham et al., 2015).
More controversial is the role of IDE in regulating
glucose homeostasis in mice. Rather than improving
glucose tolerance, deletion of the Ide gene in mice
results in the development of pronounced glucose
intolerance as well as insulin insensitivity (Farris et al.,
2003; Abdul-Hay et al., 2011; Steneberg et al., 2013). 
The function of IDE in pancreas remains largely
unknown. Stenberg et al. demonstrated that IDE is
required for insulin secretion in the IDE-KO mouse
(Steneberg et al., 2013). However, there is paucity of
data in the literature regarding IDE protein levels in
pancreatic islet cells, and its potential relationship with
pathophysiological conditions, such as DM2.
To better understand the pathophysiology of IDE in
DM2, there is a pressing need to elucidate the basic
biology of IDE in pancreatic endocrine cells. In the
present study, we investigated IDE protein levels in
alpha- and beta-cells in rodent models of obesity and
DM2 and in cadaveric human pancreata from DM2
patients. Our findings suggest that IDE may play an
important role in alpha cell function and point to insulin
levels as a critical factor for the regulation of IDE
protein levels.
Material and methods
Animal models
Animals were housed in ventilated cages on a 14-
hours light, 10-hours dark schedule at the animal facility
of the University of Valladolid (UVa, Spain). Cage
enrichment included cotton bedding. Water and food
were available ad libitum, consisting of normal chow.
Animal experiments were approved by University of
Valladolid Research Animal Ethical Committee and
JCyL authorities (protocol #5003931). 
Leptin receptor heterozygous mice BKS.Cg-
+Leprdb/+ Lepr +/OlaHsd (db/+) were purchased (Harlan,
UK) and then they were bred in our animal facility to
obtain +/+ or db/db mice. 8 week old C57Bl6/J male mice
were bought (Charles River, France) and they were fed
standard (SD) or high fat diet (60% kcal% fat, Research
Diets, USA) (HFD) for 18 weeks.
Three-month-old male Sprague Dawley rats were
born at the University of Valladolid Animal facility; they
were fed SD and water ad libitum.
Glucose and insulin determinations in mouse blood
Plasma samples were obtained from tail blood
samples of mice under fasting (16h) or non-fasting
conditions. Blood glucose levels were measured directly
from tails using the Breeze2 Glucometer (Bayer,
Germany). Plasma insulin levels were measured using
Ultrasensitive Mouse Insulin ELISA (Mercodia AB,
Sweden).
Human pancreas samples
Human pancreas samples were obtained from the
biobank of the department of pathology/Biobank of the
San Carlos Clinical Hospital in Madrid (protocol
authorized by the Ethics Committee for Clinical
Research # 12/202 and according to the Declaration of
Helsinki). Human pancreata were classified into three
groups: non-diabetic population (control), DM2 patients
treated with oral hypoglycemic agents (DM2+OHAs)
and DM2 patients undergoing insulin treatment
(DM2+Insulin). Cases were categorized by sex and age.
Controls without DM2 diagnosis were matched by age
and sex. Control, n=9; DM2+OHAs, n=9; DM2+insulin,
n=8.
The samples were selected using the following
inclusion criteria: patients aged between 40 and 80
years; pancreas control in which morphologically normal
islets were observed, suitable structure without tissue
deteriorated in hematoxylin-eosin staining; samples have
a minimum number of pancreatic islets by microscopic
examination (n≥5 per slide).
A description of each subject included in the study is
shown in Table 1.
Pancreatic islet isolation
Three-month-old male Sprague Dawley rats (fed
SD), 3-month-old db/db and +/+ mice (fed SD); and 6-
month old C57Bl6/J mice (fed SD or HFD) were
euthanized by CO2, and afterwards their pancreata were
perfused with 1.7 mg/mL collagenase P (Roche
Diagnostics, USA). Islets were isolated and purified as
previously reported (Cozar-Castellano et al., 2004).
Afterwards islets were grown in RPMI 1640 medium
supplemented with 2 mM L-glutamine, 5.5 mM D-
glucose, 10% FBS, 100 U/ml penicillin, and 100 μg/ml
streptomycin. The islets were maintained at 37°C with
5% CO2 in a humidified atmosphere.
Human islets were obtained from Dr. Olle Körsgren
lab at the University of Uppsala (Sweden) (European
Consortium for Islet Transplantation). 
Pancreas and islets staining and histomorphometry
Db/db and +/+ mice as well as HFD and SD mice
were euthanized by CO2, and afterwards their pancreata
were dissected and fixed in 10% neutral buffer formalin
overnight and embedded into paraffin blocks.
Human pancreas samples were obtained from
cadaveric donors using ultrasound imaging to obtain
tissue samples with minimum impact on the deceased
body. Pancreas samples were obtained and fixed with
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4% formaldehyde for 48-72 hours, and then embedded
into paraffin blocks. 
Five-micrometer pancreas serial sections were
obtained and stained with: Guinea pig anti-insulin
antibody (#7842, Abcam, UK), mouse anti-glucagon
antibody (#10988, Abcam, UK) and rabbit anti-IDE
antibody (#9210, Millipore, USA). The following
secondary antibodies were used: Anti- Guinea pig-Alexa
488 (#A11073, Invitrogen Ltd, Europe), Anti-Mouse-
Alexa 647 (#A21236, Invitrogen Ltd, Europe), Anti-
Rabbit-Alexa 594 (#A11012, Invitrogen Ltd, Europe).
Fluorescence images of the sections were acquired using
a NIKON Eclipse 90i microscope associated with CCD
NIKON camera (DSRi1), using a 20x objective. 
Human and rat islets were treated with 500 nM
insulin (Sigma-Aldrich, USA) at indicated time points.
Afterwards, islets were fixed with 10% neutral buffer
formalin for 1 h and embedded in paraffin blocks. Five-
micrometer sections were obtained and stained as
reported for pancreas section. Fluorescence images were
acquired in non-saturated conditions using Confocal
Leica TCS SP5 microscope, using a 63x oil immersion
objective.
The number and area of pancreatic beta- or alpha-
cells and/or IDE-positive cells; and the integrated
density (for IDE fluorescence quantification) were
quantified using ImageJ software (NIH, USA). 
INS1E cells and pancreatic islets insulin treatment
INS1E cells were a gift of Dr. Pierre Maechler
(University of Geneva, Switzerland). Cells were plated
to a density 110,000 cells/cm2 and they were grown in
RPMI 1640 Glutamax (GIBCO, NY), 11 mM Glucose,
10 mM Hepes (Invitrogen Ltd, Europe), 0.05 mM β-
Mercaptoethanol (Sigma-Aldrich, USA) 1 mM Sodium
Pyruvate (Invitrogen Ltd, Europe), 5% FBS and 1%
Penicillin- Streptomycin (Invitrogen Ltd, Europe). Cells
were cultured at 37°C with 5% CO2 in a humid
atmosphere.
Cells were seeded in 24-well plates and treated in
serum-free medium 24 hours before the experiment. 24
hours later, they were treated with serum free medium
containing 500 nM insulin (Sigma-Aldrich, USA) at
indicated time points.
Rat and human islets were plated in cell culture
inserts into 24-well plates at a density of 400 IEq (islet
equivalents) in serum-free medium overnight. 24 hours
later, islets were treated with serum medium containing
500 nM insulin at indicated time points. 
Western-blot
Islets from mice and humans were homogenized in
lysis buffer and briefly sonicated. Proteins were
quantified by the Micro BCA Kit (Thermo Scientific,
USA), separated by SDS-PAGE, and then transferred to
PDVF Immobilon-P membranes (Millipore, USA).
Blots were incubated with the following antibodies:
anti-actin (Sigma, USA) and anti-IDE (#9210,
Millipore, USA). Bound peroxidase activity was
visualized by the enhanced chemiluminescence kit
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Table 1. Demographic data of pancreas donors included in the study.
ID Sex Age Treatment Cause of death
Control HC10 M 76 Respiratory insufficiency
HC30 M 40 Septic shock 
HC23 M 54 Multiorgan failure
HC 25 M 48 Multiorgan failure
MC27 F 42 Unknown
MC15 F 75 Status epilepticus
MC22 F 52 Adult respiratory distress syndrome
MC28 F 40 Cardiogenic shock
MC21 F 63 Septic shock 
DM2+OHAs HA11 M 63 OHA (Metformin) Cardiogenic shock 
HA15 M 65 OHA (unknown) Septic shock 
HA16 M 65 OHA (unknown) Septic shock 
HA21 M 59 OHA (unknown) Unknown 
HA7 M 78 OHA (Metformin) Unknown
MA9 F 76 OHA (Metformin) Cerebral haemorrhage
MA13 F 65 OHA (Metformin) Massive pulmonary embolism
MA19 F 58 OHA (Metformin) Post surgery shock
MA16 F 69 OHA (unknown) Unknown
DM2+Insulin HI2 M 77 Insulin (unknown) Septic shock
HI16 M 60 Insulin (NPH) Cardiogenic shock 
HI15 M 67 Insulin (Mixtard 30) Acute Pulmonary Edema
HI18 M 44 Insulin (unknown) Septic shock
MI12 F 63 Insulin (unknown) Urological sepsis 
MI9 F 71 Insulin (Lantus) Pulmonary aspergillosis 
MI6 F 75 Insulin (NPH) Cardiogenic shock 
MI5 F 72 Insulin (unknown) Respiratory insufficiency
Immun-Star WesternC (Bio-Rad, EEUU). ImageJ
software (NIH, USA) was used for processing and
analysis of data. Results were normalized to control
values on each membrane.
Glucose stimulated insulin secretion (GSIS) and survival
after IDE inhibition
INS1E cells were seeded on cell culture 24-well
plates at a density of 200,000 cells per well for 72 hours.
Afterwards, they were treated for 4 hours with 500 nM
human insulin (#I9278, Sigma-Aldrich, USA), or for 30
min with 2mM 1-10 Phenantroline (#131377, Sigma-
Aldrich, USA), or both. After insulin/Phenantroline
treatment MTT and GSIS were performed.
MTT assay
Cell viability was assessed using the 3-[4,5-
dimethylthiazol-2-yl]-2,5- diphenyltetrazolium bromide
(MTT) assay method. MTT was added to each well at a
concentration of 0.5 mg/mL and plates were incubated at
37°C for 1 hour in the absence of light. The medium was
replaced with 150 μL dimethyl sulfoxide (DMSO) and
stirred for 20 min to dissolve the formazan crystals. The
absorbance for each well was measured at 562  nm using
a Microplate reader MB-580 HEALES microplate
(Shenzhen Heales Technology Development Co.,
China).
GSIS
INS1E cells were maintained the last 2 h in glucose-
free culture medium. The cells were then washed twice
and preincubated for 30 min at 37°C in glucose-free
HEPES balanced salt solution (HBSS) (114 mmol/l
NaCl, 4.7 mmol/l KCl, 1.2 mmol/l KH2P O4, 1.16
mmol/l MgSO4, 20 mmol/l HEPES, 2.5 mmol/l CaCl2,
25.5 mmol/l NaHCO3, and 0.2% bovine serum albumin[essentially fatty acid free], pH 7.2). Next, cells were
washed once with glucose-free HEPES balanced salt
solution (HBSS) and then insulin secretion was
stimulated by using static incubation for 30 min period
in 1 ml of the same buffer containing 2 or 16 mmol/l
glucose respectively. Secretion samples were measured
by Rat Insulin ELISA (Mercodia AB, Sweden). 
Statistical analysis
Statistical analysis of data was performed using the
Graph Pad Prism4 (GraphPad Software, Inc., La Jolla,
CA, USA). Distribution of variables was checked using
the Kolmogorov-Smirnov test. Comparisons between
two groups were performed using Student’s t-test;
comparisons between more than two groups were
performed by ANOVA followed by Tukey’s Multiple
Comparison Test. Differences were considered
significant at p<0.05.
Results
IDE is expressed in pancreatic alpha- and beta-cells of
rodents and humans
To determine whether IDE is expressed in insulin-
and glucagon-producing cells, we validated our antibody
for IDE staining using pancreata of IDE null mice
(Abdul-Hay et al., 2011); no staining was observed in
the null tissue (Fig. 1). Staining of multiple tissues
revealed that IDE is expressed in both beta- and alpha-
cells of wild type mouse and human pancreata (Fig. 1).
Of note, IDE staining was more intense in glucagon
positive-cells of both species relative to beta-cells or
other pancreatic cells (such as exocrine cells), indicating
a higher expression of IDE in alpha-cells.
IDE protein level is augmented in islet-cells of preclinical
models of hyperinsulinemia
To investigate whether IDE protein level varies in
the context of preclinical hyperinsulinemia we
investigated islet IDE protein level in db/db and HFD
mouse models. Twelve-week-old db/db mice were
hyperinsulinemic (5.0 ng/mL vs. 0.5 ng/mL, p<0.05) and
diabetic (450 mg/dL vs. 150 mg/dL, p<0.05). Twenty-
six-week-old male C57Bl6J mice fed with a HFD were
hyperinsulinemic (16.9 ng/mL vs. 1.0 ng/mL, p<0.05)
and mildly hyperglycemic (153 mg/dL vs. 119 mg/dL,
p<0.05). Insulin and glucose levels are non-fasting.
We stained pancreata of WT and db/db mice for
IDE, insulin and glucagon. IDE-integrated intensity was
measured for alpha- and beta-cells and those intensities
were then divided by glucagon and insulin areas
respectively (Fig. 2A). We did not detect IDE protein
level differences in pancreata freshly obtained from
db/db versus wild-type mice. Surprisingly, however,
when islets were isolated and western-blots were
performed, a significant 50% increase in IDE protein
level was detected (Fig. 2B,C). Similar results were
observed for HFD-treated pancreata: the integrated
intensity of IDE was similar in HFD-treated mice as
compared to control animals fed a standard diet (SD)
(Fig. 2D); but there is a significant 30% increase in IDE
protein level in HFD isolated islets when detected by
western-blotting (Fig. 2E,F). Of note, WT (+/+)
pancreata (Fig. 2A), SD and HFD pancreata (Fig. 2D)
showed augmented IDE levels in alpha- compared to
beta-cell population.
Human type-2 diabetic islets show impaired beta-cell to
alpha-cell ratio
Before studying expression of IDE in human
pancreata of control and diabetic patients, we
characterized their alpha- and beta-cell populations. A
histomorphometric study was performed in parallel
using two methods of quantification (a) alpha- or beta-
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Fig. 1. Validation of IDE antibody for immunostaining. Insulin (green), glucagon (pink), IDE (red) and DAPI (blue) were stained in IDE null and wild-type
(WT) mice, as well as in human pancreata. Scale bars: 50 μm.
Fig. 2. IDE expression in preclinical models of diabetes and obesity. A. IDE integrated density per insulin and glucagon area was measured in
pancreas of wild-type (+/+) or db/db mice. N=18 +/+; N=9 db/db B. Representative IDE western blot of +/+ and db/db islets. C. Quantification of IDE in
islets of +/+ and db/db mice. N=4 +/+; N=5 db/db. D. IDE integrated density per insulin and glucagon area was measured in pancreas of mice fed with
standard diet (SD) or high-fat diet (HFD). N=8 SD; N=6 HFD. E. Representative IDE western blot of SD and HFD islets. F. Quantification of IDE in islets
of SD and HFD mice. N=3 SD; N=5 HFD. One pancreas section was used per animal for each kind of staining. *p<0.05 versus control (+/+); $ p<0.05
versus β Area; # p<0.05 versus SD.
cell number per total islet cell number and (b) alpha- or
beta-cell area per pancreas area. 
Representative pictures of insulin and glucagon
staining in control, DM2+OHAs and DM2+insulin
pancreata are shown in Fig. 3A,B. DM2 pancreata
(detailed information in Table 1) showed no difference
in beta-cell numbers when compared to control
pancreata, but a significant 40% decrease in beta-cell
area in insulin-treated DM2 patients (Fig. 4A).
Presenting an opposite profile, DM2 pancreata displayed
a significant 30% increase in alpha-cell numbers (Fig.
4B), but no differences in alpha-cell area. These results
point to an increase in alpha-cell numbers per islet
without increasing alpha-cell area per pancreas.
Interestingly, pancreas from DM2 patients showed a
50% reduction in beta-/alpha-cell ratio independently of
the method used for its quantification (Fig. 4C). These
data are indicative of impaired DM2 pancreatic
endocrine cell distribution, which parallels dysfunction
in the secretion of insulin and glucagon (Kahn et al.,
2014; Moon and Won, 2015).
IDE protein level is down-regulated in islets of DM2
patients treated with OHAs and up-regulated in DM2
patients treated with insulin
Understanding that different anti-diabetic treatments
might differentially affect IDE protein level, we elected
to separately investigate IDE protein levels in pancreatea
from DM2 patients treated with OHAs versus those
treated with insulin. Representative pictures of
insulin/IDE and glucagon/IDE staining in control,
DM2+OHAs and DM2+insulin pancreata are shown in
Fig. 5. Quantification of IDE intensity per beta- or
alpha-cell area showed a 100-300% increase in IDE
protein levels in alpha-cells versus beta-cells (Fig. 6A).
This result quantitatively demonstrates that IDE is
expressed in higher amounts in alpha than in beta-cells.
These results nicely correlate to those for rodents in Fig.
2A,D.
Interestingly, whereas DM2+OHAs pancreata
showed a significant 40% decrease in IDE protein level
in beta-cells compared to control subjects, DM2+insulin
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Fig. 3. β- and α-cells distribution in human pancreata. Control, non-diabetic donor; DM2, type-2 diabetic donor; DM2+OHAs, type-2 diabetic donor
treated with oral anti-diabetic agents; DM2+insulin, type-2 diabetic donor treated with insulin. A, B. Representative pictures of insulin staining (green),
glucagon (pink) and DAPI (blue). Scale bars: 50 µm.
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Fig. 4. β- and α-cells
quantif ication in human
pancreata. A. Percentage of
insulin-positive cells per total
islet cell number; and beta-cell
area/islet area. B. Percentage of
glucagon-positive cells per total
islet cell number; and alpha-cell
area/islet area. C. Ratio of beta-
per alpha-cell number; and ratio
beta- per alpha-cell area.
pancreata displayed increased IDE protein level as
compared to DM2+OHAs (Fig. 6B,C). This is an
interesting outcome that distinguishes two different
kinds of type-2 diabetics. In alpha-cells, on the other
hand, we did not detect significant changes in IDE
protein levels (Fig. 6D,E).
Of note, diabetes reduces IDE protein levels in beta-
cells, but under insulin treatment IDE is upregulated
returning to normal (Fig. 6C). These results point to a
potential effect of insulin on stimulation of IDE levels.
Insulin treatment induces IDE protein level in INS1E and
islet cells in vitro
In view of our results in DM2 patients, showing
decreased IDE protein level in OHAs-treated diabetics
but increased IDE protein level in insulin-treated-DM2
subjects, we hypothesized that insulin produces IDE up-
regulation. In an attempt to elucidate the potential
influence of insulin treatment on IDE levels, we cultured
INS1E cells and isolated rat and human islets and treated
them in vitro with insulin for a period of 1 to 4 h.
Afterwards, IDE protein level was measured by western
blotting and/or immunostaining. IDE level in INS1E
cells was found to be significantly increased by 40-70%
after 4 h of insulin treatment (Fig. 7A-D); similarly, IDE
was increased by 60% in rat and human islets (Fig. 8A-E
respectively). Interestingly, IDE is 50% increased in
pancreatic- beta-cells. These results suggest that insulin
is responsible for the relative upregulation of IDE
observed in insulin-treated diabetic patients versus
OHAs-treated patients.
Implications of IDE activity on beta-cell biology
To shed light on the possible physiological role of
the insulin-mediated IDE up-regulation on beta-cell
survival and function, we have performed experiments
treating INS1E cells with the IDE inhibitor
Phenantroline +/- insulin. We have measured cell
viability by MTT observing no changes in beta-cell
survival after 30 min Phenantroline treatment (Fig. 9A).
Furthermore, IDE inhibition showed impaired beta-cell
function as measured by GSIS. Interestingly, 4 h insulin
treatment, although increasing IDE protein levels (Fig.
7), impairs GSIS as well (Fig. 9B). Thus, both,
increment and decrease of IDE function, result in
inhibition of insulin secretion.
Discussion
Diabetes is a costly and increasingly common
disease which requires a clearer understanding of its
molecular mechanisms, improved treatments with fewer
side effects, as well as novel biomarkers to determine in
an easy and non-invasive way the evolution of the
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Fig. 5. IDE staining in endocrine human pancreata. Representative pictures of IDE/insulin (green/pink) and IDE/glucagon staining (red/pink). Scale
bars: 50 µm.
disease and the response to patients’ treatments. The Ide
locus has been genetically linked to the risk of suffering
both diabetes and hyperinsulinemia (Karamohamed et
al., 2003; Gu et al., 2004; Schulze et al., 2007; Sladek et
al., 2007; Kwak et al., 2008), yet, surprisingly, IDE
protein levels have not previously been quantified by
staining in any animal or human tissue, neither under
physiological nor pathophysiological conditions. Here,
we have conducted for the first time a cell-specific study
in beta- and alpha-cells comparing IDE protein levels in
human DM2 patients versus control subjects, as well as
in multiple murine models of hyperinsulinemia.
Furthermore, we conducted the first comparative study
of IDE protein levels on OHAs versus insulin-treated
DM2 patients.
Our results highlight the relevance of IDE in DM2
and include a number of findings. First, in agreement
with previous publications (Yoon et al., 2003), DM2
patients show an impaired beta-/alpha-cell ratio. It is
relevant to emphasize that using different
histomorphometric analysis in the same samples
sometimes ends in controversial results as seen in the
literature (Sakuraba et al., 2002; Butler et al., 2003;
Yoon et al., 2003; Rahier et al., 2008). Beta-/alpha-cell
ratio results are greatly consistent in our hands, showing
by both methodologies to be decreased in diabetic
population. Second, IDE was found to be highly
expressed in pancreatic alpha-cells, with lower levels
present in beta-cells. Third, IDE levels were increased in
islet cells from db/db and HFD mice as compared to
their respective controls. Interestingly, western-blotting
showed to have higher sensitivity than fluorescence
quantification to this end. Fourth, IDE protein level was
decreased in beta-cells of DM2+OHAs patients, but
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Fig. 6. IDE expression in endocrine
human pancreata. A. Comparison of
IDE integrated density by beta-cell
area and IDE integrated density by
alpha-cell area. B, C. IDE integrated
density per insulin area. D, E. IDE
integrated density per glucagon
area. N=9 control; N=9 DM2+OHA;
N=8 DM2+Insulin. *p<0.05 versus
Control; #p<0.05 versus DM2+OHA;
$p<0.05 versus β Area.
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Fig. 7. IDE is upregulated in INS1E cells after insulin treatment.
A. Representative western blot of IDE expression in INS1E cells
unstimulated (Ctrl) or stimulated with 500nM insulin for 1 to 4
hours. N=3. B. Quantification of IDE by western blotting in
INS1E cells stimulated with insulin. C. Representative pictures
of insulin (green) and IDE staining (red) in INS1E cells
stimulated with insulin. D. IDE integrated density per insulin
area in INS1E cells stimulated with insulin. N=3. Scale bars: 50
µm.
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Fig. 8. IDE is upregulated in human and rodent pancreatic islet-cells after insulin treatment. A. Representative pictures of insulin (green) and IDE
staining (red) in rat islets stimulated with insulin. B. IDE integrated density per insulin area in rat islets stimulated with insulin. N=18-21. C. IDE
integrated density per glucagon area in rat islets stimulated with insulin. N=12-14. D. Representative western-blot of IDE expression in human islets no
stimulated (Ctrl) or stimulated with 500 nM insulin for 1 to 8 hours. E. Quantification of IDE by western blotting in human islets stimulated with insulin.
N=2 different human islet preparations. *p<0.05 versus Control. Scale bars: 25 μm.
comparatively upregulated in beta-cells of DM2+insulin
patients. Finally, we established that insulin treatment of
isolated rodent and human islets induces IDE
overexpression.
Steneberg et al. (2013) have previously shown by
western-blot that IDE protein level is decreased by 40%
in whole islets of DM2 patients compared to controls.
This study did not report the age, sex or treatment of
these patients, but their results nicely correlate with our
finding in beta-cells of DM2+OHAs patients. Steneberg
and colleagues study showed that genetic deletion of IDE
impairs glucose stimulated insulin secretion in beta-cells
which is a hallmark of DM2. Our results go one step
further: here we have characterized two different
populations of DM2 patients, treated with OHAs versus
insulin, and we have performed specific detection of IDE
in beta- and alpha-cells showing that loss of IDE levels
occurs specifically in beta-cells but not alpha-cells. 
Furthermore, although beta-cells from OHAs-treated
DM2 subjects show reductions in IDE protein levels, as
reported by Steneberg and colleagues, insulin-treated
subjects showed no changes relative to controls. Insulin-
treated subjects, however, showed significant increases
in IDE protein level in beta-cells relative to OHAs-
treated patients. These results nicely correlate with those
in hyperinsulinemic islets of db/db and HFD mice. At
the same time, this finding suggested that insulin
treatment stimulates elevated IDE protein levels, which
we confirmed through multiple experiments in INS1E
cells and rodent and human islets. IDE activity inhibition
using Phenantroline suggests a physiological role of IDE
on insulin secretion, in accordance with Steneberg et al
(Steneberg et al., 2013). Interestingly, the result of GSIS
after insulin stimulus may suggest an IDE-independent
mechanism for GSIS in hyperinsulinemia.
IDE upregulation under high insulin conditions may
be part of a counterregulatory islet adaptation to produce
insulin clearance in this hyperinsulinemic
microenvironment. This is possible because insulin not
cleared by liver and kidney is ultimately removed by
other insulin-sensitive cells (Duckworth et al., 1998).
Other studies in liver have already shown that
insulin levels can regulate IDE protein expression. An
obesity-induced hyperinsulinemic mouse model showed
lower IDE levels that were upregulated after taurine
conjugated bile acid (TUCDA) (Vettorazzi et al., 2017).
Interestingly, a different study by the same group has
shown that hyperinsulinemia caused by glucocorticoid
treatment may be due to decreased IDE activity (Protzek
et al., 2016).
Our findings reveal new insights into the
involvement of IDE in endocrine pancreatic function as
well as its response to DM2 subjects treated with
different anti-diabetic therapies. At the same time, they
raise a significant number of new questions. Why does
insulin simulate the expression of IDE? Does this
represent a homeostatic mechanism whereby high
insulin levels promote the degradation of insulin? Is it
helpful or harmful that IDE levels return to normal in
DM2+insulin beta-cells?
Insulin is secreted through the classical secretory
pathway; meanwhile IDE is not (Zhao et al., 2009).
While they might be expressed in the same cells, IDE
and insulin would not be expected to reside within the
same cell compartments. If not, where does IDE interact
with insulin? Our findings open new lines of thinking
around this intriguing protein. Further research is
warranted to investigate the subcellular localization of
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Fig. 9. Beta-cell viability and function after insulin treatment. A. Cell viability was measured in INS1E cells by MTT after 4h insulin, 30 min Phenantroline
or Insulin+Phenatroline treatment (500 nM insulin; 2 mM 1-10 Phenantroline). B. Glucose stimulated insulin secretion was measured after 4h insulin, 30
min Phenantroline or Insulin+Phenatroline treatment. N=6 for both experiments. *p<0.05 versus Ctrl-2mM; #p<0.05 versus Ctrl-16mM.
IDE and to identify possible sites of interaction with
insulin inside and outside the beta-cell.
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